Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors

- Tang, Gong, Cuzick, Jack, Costantino, Joseph P., Dowsett, Mitch, Forbes, John F., Crager, Michael, Mamounas, Eleftherios P., Shak, Steven, Wolmark, Norman

Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study

- Cuzick, Jack, Warwick, Jane, Pinney, Elizabeth, Duffy, Stephen W., Cawthorn, Simon, Howell, Anthony, Forbes, John F., Warren, Ruth M. L.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

- Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

- Dowsett, Mitch, Cuzick, Jack, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study

- Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

- Sestak, Ivana, Cuzick, Jack, Sapunar, Francisco, Eastell, Richard, Forbes, John F., Bianco, Angelo R., Buzdar, Aman U.